No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
XBI SPDR S&P Biotech ETF
- 90.595
- +1.465+1.64%
Trading Jun 3 13:04 ET
92.975High89.250Low
92.975High89.250Low7.55MVolume89.970Open89.130Pre Close692.46MTurnover10.06%Turnover Ratio--P/E (Static)75.00MShares103.52052wk High--P/B6.79BFloat Cap63.78952wk Low0.02Dividend TTM75.00MShs Float174.706Historical High0.02%Div YieldTTM4.18%Amplitude21.378Historical Low91.746Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | CNBC Halftime Report Final Trades: American Express, The Trade Desk, SPDR Series Trust SPDR S&P Biotech ETF
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.Shares of Stericycle, Inc. (NASDAQ:SRCL) rose sharply during Monday's session after the company inked a deal to be
Moderna And Merck Announced The First Presentation Of Results From A Planned Analysis From The Phase 2B KEYNOTE-942/mRNA-4157-P201 Study Of MRNA-4157 (V940) Plus Keytruda In Patients With Resected High-risk Melanoma Following Complete Resection (N=157)
With a median follow-up of approximately three years (34.9 months), adjuvant treatment with mRNA-4157 (V940) in combination with KEYTRUDA continued to demonstrate a clinically meaningful and durable i
Breaking Down Moderna: 7 Analysts Share Their Views
During the last three months, 7 analysts shared their evaluations of Moderna (NASDAQ:MRNA), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, shed
Moderna Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/03/2024 — Needham Reiterates → Hold 05/14/2024 -16.29% Evercore ISI Group → $120 Initiates Coverage On
Stocks Most Shunned by Hedge Funds and Mutual Funds
Comments
Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
3
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Pfizer(PFE.US$ $Dynavax Technologies(DVAX.US$ $Sandstorm Gold(SAND.US$ $Bristol-Myers Squibb(BMY.US$ $SPDR S&P Biotech ETF(XBI.US$
$Pfizer(PFE.US$ $Dynavax Technologies(DVAX.US$ $Sandstorm Gold(SAND.US$ $Bristol-Myers Squibb(BMY.US$ $SPDR S&P Biotech ETF(XBI.US$
10
1
$SPDR S&P Biotech ETF(XBI.US$
Assumptions: Overall market is stable and not turning into bear market; US economy no recession; Better to start rate cut in 2024.
$Nasdaq Composite Index(.IXIC.US$ $S&P 500 Index(.SPX.US$
Assumptions: Overall market is stable and not turning into bear market; US economy no recession; Better to start rate cut in 2024.
$Nasdaq Composite Index(.IXIC.US$ $S&P 500 Index(.SPX.US$
1
1
$SPDR S&P Biotech ETF(XBI.US$ $iShares Biotechnology ETF(IBB.US$
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US$ 's $4.3 b...
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US$ 's $4.3 b...
6
Read more